Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Medical centers spearhead China's pharma push
Science ( IF 56.9 ) Pub Date : 2017-11-09 , DOI: 10.1126/science.358.6364.709 Dennis Normile 1
Science ( IF 56.9 ) Pub Date : 2017-11-09 , DOI: 10.1126/science.358.6364.709 Dennis Normile 1
Affiliation
China’s pharma industry has limited R&D capabilities. Struggling under heavy patient loads, clinicians have little time for research and academics are under pressure to churn out peer-reviewed papers. As a result, universities have spun off few biotech ventures. Also hindering innovation are a slow regulatory review process and lax intellectual property protection. Now, China is endeavoring to raise its game in biomedicine. It’s launching five new translational medicine centers, each showered with $150 million in startup funds for buildings and instruments. And last month, China issued guidelines for overhauling the nation’s drug approval process by reforming clinical trial management, speeding reviews, allowing submission of foreign clinical trial data, and promoting innovation in drug and medical device development.
更新日期：2017-11-09
京公网安备 11010802027423号